Mirati Therapeutics Gestione

Gestione criteri di controllo 3/4

Mirati Therapeutics Il CEO è Chuck Baum, nominato in Nov2012, e ha un mandato di 11.17 anni. la retribuzione annua totale è $ 7.42M, composta da 9.2% di stipendio e 90.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di R$ 32.75M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 5.1 anni.

Informazioni chiave

Chuck Baum

Amministratore delegato

US$7.4m

Compenso totale

Percentuale dello stipendio del CEO	9.2%
Mandato del CEO	11.2yrs
Proprietà del CEO	0.2%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chuck Baum rispetto agli utili di Mirati Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2023	n/a	n/a	-US$726m
Jun 30 2023	n/a	n/a	-US$738m
Mar 31 2023	n/a	n/a	-US$737m
Dec 31 2022	US$7m	US$685k	-US$741m
Sep 30 2022	n/a	n/a	-US$738m
Jun 30 2022	n/a	n/a	-US$645m
Mar 31 2022	n/a	n/a	-US$634m
Dec 31 2021	US$18m	US$662k	-US$582m
Sep 30 2021	n/a	n/a	-US$483m
Jun 30 2021	n/a	n/a	-US$491m
Mar 31 2021	n/a	n/a	-US$407m
Dec 31 2020	US$12m	US$615k	-US$358m
Sep 30 2020	n/a	n/a	-US$329m
Jun 30 2020	n/a	n/a	-US$296m
Mar 31 2020	n/a	n/a	-US$259m
Dec 31 2019	US$8m	US$597k	-US$213m
Sep 30 2019	n/a	n/a	-US$169m
Jun 30 2019	n/a	n/a	-US$142m
Mar 31 2019	n/a	n/a	-US$125m
Dec 31 2018	US$5m	US$580k	-US$98m
Sep 30 2018	n/a	n/a	-US$88m
Jun 30 2018	n/a	n/a	-US$77m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$2m	US$563k	-US$70m

Compensazione vs Mercato: La retribuzione totale di Chuck ($USD 7.42M ) è superiore alla media delle aziende di dimensioni simili nel mercato BR ($USD 1.29M ).

Compensazione vs guadagni: La retribuzione di Chuck è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chuck Baum (65 yo)

11.2yrs

Mandato

US$7,420,213

Compensazione

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
James Christensen	Executive VP & Chief Scientific Officer	10yrs	US$5.01m	0.082% R$ 16.8m
Alan Bart Sandler	Executive VP & Chief Medical Officer	1.2yrs	US$5.30m	0.014% R$ 2.9m
Aaron Ondrey	Chief Financial Officer	less than a year	Nessun dato	0.056% R$ 11.5m
Betsy Gelfand	Chief Accounting Officer	less than a year	Nessun dato	Nessun dato
John Moriarty	Chief Legal Officer & Corporate Secretary	less than a year	Nessun dato	Nessun dato
Peter Lee	Chief Compliance Officer	2yrs	Nessun dato	Nessun dato
Michael Paolucci	Chief People Officer	2yrs	Nessun dato	Nessun dato
Benjamin Hickey	Chief Commercial Officer	4yrs	US$6.93m	0.040% R$ 8.1m
Kelly Covello	VP & Head of Medical Affairs	3.8yrs	Nessun dato	Nessun dato
Ryan Asay	VP & Head of Corporate Affairs	3.8yrs	Nessun dato	Nessun dato
Susan Welsh	Senior VP of Pharmacovigilance & Chief Safety Officer	3yrs	Nessun dato	Nessun dato

2.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di M2RT34 è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% R$ 32.8m
Bruce Leonard Carter	Independent Director	7.3yrs	US$700.41k	0.0086% R$ 1.8m
George Demetri	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Faheem Hasnain	Chairman & Lead Independent Director	4.9yrs	US$979.79k	0.012% R$ 2.6m
Julie Michele Cherrington	Independent Director	4.6yrs	US$697.91k	0% R$ 0
Stephen Baylin	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Lillian Siu	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Aaron Davis	Independent Director	5.1yrs	US$677.91k	0.061% R$ 12.6m
Pasi Antero Janne	Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Craig Johnson	Independent Director	10.3yrs	US$702.91k	0.0086% R$ 1.8m
Channing Der	Member of Scientific Advisory Board	5yrs	Nessun dato	Nessun dato
Maria Martinez-Davis	Independent Director	5.1yrs	US$695.41k	0.0086% R$ 1.8m

5.1yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di M2RT34 sono considerati esperti (durata media dell'incarico 5.1 anni).

Mirati Therapeutics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media